Cancer Research and Treatment10.4143/crt.2019.1862020521292-300Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in KoreaKangkook Lee, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn,,
Clinical Lung Cancer10.1016/j.cllc.2015.12.0112016174292-300Patients With Advanced Non–Small Cell Lung Cancer Requiring Inpatient Medical Oncology Consultation: Characteristics, Referral Patterns, and OutcomesJoanna Gotfrit, Tinghua Zhang, Silvia Zanon-Heacock, Paul Wheatley-Price,
Clinical Lung Cancer10.3816/clc.2010.n.00120101118-12A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Non–Small-Cell Lung CancerRamaswamy Govindan,
10.21203/rs.2.10908/v12019Treatment Outcome and Clinical Characteristics of HER2 Mutated Advanced Non-Small Cell Lung Cancer Patients in ChinaFei Xu, Guangjian Yang, Haiyan Xu, Lu Yang, Weini Qiu, Junling Li, Yan Wang,
Annals of Oncology10.1093/annonc/mdv434.02201526vii40Screening for HER2 alterations and HER2-targeted therapy in non-small cell lung cancerIchiro Kinoshita,,
Clinical Lung Cancer10.1016/j.cllc.2018.05.0082018195e759-e766Comparing Outcomes of Patients With Early-Stage Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty StatusGovind Raghavan, Narek Shaverdian, Shawna Chan, Fang-I. Chu, Percy Lee,
Lung Cancer10.1016/s0169-5002(11)70102-7201171S35-S36102 Radical radiotherapy outcomes in stage I and II non-small cell lung cancer patients unfit for surgeryG. Ekatah, H.K. Lord,
Lung Cancer10.1016/0169-5002(95)96430-41995121-2149Phase I clinical study of KW-2307 combined with cisplatin in non-small cell lung cancer patients,
Clinical Lung Cancer10.1016/s1525-7304(11)70793-819991168-69Commentary on “Prognostic Markers in Resected Stage I and II Non–Small-Cell Lung Cancer Patients”David H. Harpole,
ESMO Open10.1016/j.esmoop.2021.100260202165100260Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterationsM. Riudavets, I. Sullivan, P. Abdayem, D. Planchard,